These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24905399)

  • 1. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
    Malarvizhi GL; Retnakumari AP; Nair S; Koyakutty M
    Nanomedicine; 2014 Nov; 10(8):1649-59. PubMed ID: 24905399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine.
    Chandran P; Gupta N; Retnakumari AP; Malarvizhi GL; Keechilat P; Nair S; Koyakutty M
    Nanomedicine; 2013 Nov; 9(8):1317-27. PubMed ID: 23669368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
    Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
    Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
    Zhang X; Li J; Yan M
    Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
    Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
    Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
    Duan W; Liu Y
    Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
    Tom G; Philip S; Isaac R; Praseetha PK; Jiji SG; Asha VV
    Life Sci; 2018 Aug; 206():10-21. PubMed ID: 29709652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
    Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
    Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
    Sun W; Wang Y; Cai M; Lin L; Chen X; Cao Z; Zhu K; Shuai X
    Biomater Sci; 2017 Nov; 5(12):2468-2479. PubMed ID: 29106433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
    Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
    Schmithals C; Köberle V; Korkusuz H; Pleli T; Kakoschky B; Augusto EA; Ibrahim AA; Arencibia JM; Vafaizadeh V; Groner B; Korf HW; Kronenberger B; Zeuzem S; Vogl TJ; Waidmann O; Piiper A
    Cancer Res; 2015 Aug; 75(15):3147-54. PubMed ID: 26239478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
    Park W; Chen J; Cho S; Park SJ; Larson AC; Na K; Kim DH
    ACS Appl Mater Interfaces; 2016 May; 8(20):12711-9. PubMed ID: 27159350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing.
    Malarvizhi GL; Chandran P; Retnakumari AP; Ramachandran R; Gupta N; Nair S; Koyakutty M
    Nanomedicine; 2014 Apr; 10(3):579-87. PubMed ID: 24200524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity.
    Rouleau L; Antony AN; Bisetto S; Newberg A; Doria C; Levine M; Monti DA; Hoek JB
    Free Radic Biol Med; 2016 Jun; 95():308-322. PubMed ID: 27036367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
    Cao H; Wang Y; He X; Zhang Z; Yin Q; Chen Y; Yu H; Huang Y; Chen L; Xu M; Gu W; Li Y
    Mol Pharm; 2015 Mar; 12(3):922-31. PubMed ID: 25622075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
    Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
    J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.
    Sui J; Cui Y; Cai H; Bian S; Xu Z; Zhou L; Sun Y; Liang J; Fan Y; Zhang X
    Nanoscale; 2017 Feb; 9(8):2755-2767. PubMed ID: 28155940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
    Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
    Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
    Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
    Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.